KR890014544A - 비스(히드록시메틸)시클로부틸 푸린 및 피리미딘 - Google Patents
비스(히드록시메틸)시클로부틸 푸린 및 피리미딘 Download PDFInfo
- Publication number
- KR890014544A KR890014544A KR1019890003979A KR890003979A KR890014544A KR 890014544 A KR890014544 A KR 890014544A KR 1019890003979 A KR1019890003979 A KR 1019890003979A KR 890003979 A KR890003979 A KR 890003979A KR 890014544 A KR890014544 A KR 890014544A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- phosphorus compounds
- hydroxymethyl
- bis
- cyclobutyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/04—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (31)
- 하기 일반식 1을 갖는 화합물 및 제약상 허용되는 그의 염.식중, R1은이고, R2는 수소, 메틸, 플루오로, 클로로, 브로모, 요오드, 히드록시 또는 아미노기이고, R3는 플루오로, 클로로, 브로도, 요오도, 수소, 메틸 트리플루오로메틸, 에틸, n-프로필, 2-플루오로에틸, 2-클로로에틸 또는(식중, R4는 클로로, 브로모, 요오도, 수소, 메틸 또는 트리플루오로메틸기임)이고, R5는 알킬기이고, R6는 수소, 알킬 치환알킬 또는 아릴기이고, R7및 R8은 각각 독립적으로 수소, -PO3H2또는이다.
- 제1항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제2항에 있어서, R1이인 화합물.
- 제1항에 있어서, R7및 R8이 독립적으로 수소 또는인 화합물.
- 제1항에 있어서, R7및 R8이 독립적으로 수소 또는 -PO3H2인 화합물.
- 제1항에 있어서, R7및 R8이 수소인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, R1이인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-9-[2,3-비스(히드록시메틸)시클로부틸]구아닌인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3β)-3-(6-아미노-9H-푸린-9-일)-1,2-시클로부탄-디메탄올인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-1-[2,3-비스(히드록시메틸)시클로부틸]-5-메틸-2,4-(1H,3H)-피리미딘디온인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-4-아미노-1-[2,3-비스(히드록시메틸)시클로부틸]-2-(1H)-피리미디논인 화합물.
- 제1항에 있어서, 화합물이 (1α(E), 2β, 3α)-1-[2,3-비스(히드록시메틸)시클로부틸]-5-(2-브로모에테닐)-2,4-(1H,3H)-피리미딘디온인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-2-아미노-9-[2,3-비스(히드록시메틸)시클로부틸]-8-브로모-1,9-디히드로-6H-푸린-6-온인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-1-[2,3-비스(히드록시메틸)시클로부틸]-5-요오도-2,4-(1H,3H)-피리미딘디온인 화합물.
- 제1항에 있어서, 화합물이 (1α, 2β, 3α)-5-아미노-3-[2,3-비스(히드록시메틸)시클로부틸]-3,6-디히드로-7H-1,2,3-트리아졸로[4,5-d]-피리미딘-7-온인 화합물.
- 하기 구조식의 화합물식중, P는 히드록시 보호기임.
- 하기 구조식의 화합물식중, P는 히드록시 보호기임.
- 하기 구조식의 화합물식중, X는 이탈기이고, P는 히드록시 보호기임.
- 제30항에 있어서, X가 클로로, 브로모, 요오도, 아릴술포네이트 또는 알킬술포네이트기인 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US175,376 | 1980-08-06 | ||
US17537688A | 1988-03-30 | 1988-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890014544A true KR890014544A (ko) | 1989-10-24 |
KR970009223B1 KR970009223B1 (ko) | 1997-06-09 |
Family
ID=22640016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890003979A KR970009223B1 (ko) | 1988-03-30 | 1989-03-29 | 비스(히드록시메틸)시클로부틸 푸린 및 피리미딘 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5723609A (ko) |
EP (1) | EP0335355B1 (ko) |
JP (1) | JP2694999B2 (ko) |
KR (1) | KR970009223B1 (ko) |
CN (1) | CN1031054C (ko) |
AR (1) | AR247395A1 (ko) |
AT (1) | ATE158797T1 (ko) |
AU (2) | AU616494B2 (ko) |
BR (1) | BR1100660A (ko) |
CA (1) | CA1341201C (ko) |
CZ (1) | CZ278493B6 (ko) |
DD (1) | DD280325A5 (ko) |
DE (1) | DE68928353T2 (ko) |
DK (1) | DK170749B1 (ko) |
EG (1) | EG18734A (ko) |
ES (1) | ES2109218T3 (ko) |
FI (1) | FI96420C (ko) |
GR (1) | GR3025693T3 (ko) |
HU (1) | HU203734B (ko) |
IE (1) | IE81079B1 (ko) |
IL (1) | IL89796A (ko) |
MX (1) | MX15464A (ko) |
NO (1) | NO168423C (ko) |
NZ (1) | NZ228490A (ko) |
PH (1) | PH26562A (ko) |
PL (1) | PL158539B1 (ko) |
PT (1) | PT90159B (ko) |
RU (2) | RU2041213C1 (ko) |
SK (1) | SK278165B6 (ko) |
YU (1) | YU63789A (ko) |
ZA (1) | ZA892185B (ko) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597824A (en) * | 1987-11-03 | 1997-01-28 | Abbott Laboratories | Analogs of oxetanyl purines and pyrimidines |
AU622926B2 (en) * | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
JP2577640B2 (ja) * | 1988-09-09 | 1997-02-05 | 日本化薬株式会社 | 新規なシクロブタン誘導体 |
US5153352A (en) * | 1988-10-25 | 1992-10-06 | Bristol-Myers Squibb Company | Process for preparation of intermediates of carbocyclic nucleoside analogs |
IL92096A0 (en) | 1988-10-25 | 1990-07-12 | Abbott Lab | Carboxylic nucleoside analogs |
US5246931A (en) * | 1988-10-25 | 1993-09-21 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5145960A (en) * | 1989-04-24 | 1992-09-08 | E. R. Squibb & Sons, Inc. | Pyrimidinyl tetrahydrofurans |
US5164520A (en) * | 1989-04-24 | 1992-11-17 | E. R. Squibb & Sons, Inc. | Intermediates for purinyl and pyrimidinyl tetrahydrofurans |
NZ232993A (en) * | 1989-04-24 | 1992-10-28 | Squibb & Sons Inc | Purinyl and pyrimidinyl tetrahydrofurans |
JPH03173896A (ja) * | 1989-09-08 | 1991-07-29 | Nippon Kayaku Co Ltd | 新規オキセタノシン誘導体、その塩およびその用途 |
US5256806A (en) * | 1989-12-18 | 1993-10-26 | E. R. Squibb & Sons, Inc. | Intermediates for the preparation of optically active cyclobutane nucleoside |
US5198583A (en) * | 1989-12-18 | 1993-03-30 | E. R. Squibb & Sons, Inc. | Optically active cyclobutane nucleoside and intermediates, therefor |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
US5352669A (en) * | 1990-03-13 | 1994-10-04 | The Of The United States Of America As Represented By The Department Of Health And Human Services | O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity |
US5691307A (en) * | 1990-03-13 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | O6 -substituted guanine compositions and methods for depleting O6 |
US5235052A (en) * | 1990-04-16 | 1993-08-10 | Bristol-Myers Squibb Company | Process for preparing substituted cyclobutane purines |
JPH0421682A (ja) * | 1990-05-11 | 1992-01-24 | Asahi Chem Ind Co Ltd | 2―フルオロネプラノシンaおよびその製造法 |
US5344962A (en) * | 1990-05-24 | 1994-09-06 | E. R. Squibb & Sons, Inc. | Intermediates in the synthesis of an optically active cyclobutane nucleoside |
CA2042931A1 (en) * | 1990-05-24 | 1991-11-25 | Robert Zahler | Fluorinated bis (hydroxymethyl) cyclobutyl purines and pyrimidines |
US5324730A (en) * | 1990-05-24 | 1994-06-28 | Nippon Kayaku Kabushiki Kaisha | Phenoxyphosphoryloxymethyl cyclobutyl purines |
IE72143B1 (en) * | 1990-05-24 | 1997-03-26 | Squibb & Sons Inc | Process for preparing an optically active cyclobutanone an intermediate in the synthesis of an optically active cyclobutane nucleoside |
US5233076A (en) * | 1990-05-24 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside |
US5374625A (en) * | 1990-07-24 | 1994-12-20 | Nippon Kayaku Kabushiki Kaisha | Adenine and guanine derivatives for the treatment of hepatitis virus infections |
CA2052315A1 (en) * | 1990-10-09 | 1992-04-10 | Masashi Nagai | Cyclobutane derivatives |
USH1142H (en) * | 1990-11-05 | 1993-02-02 | Optically active cyclobutyl pyrimidine | |
US5233086A (en) * | 1991-10-02 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Intermediates for the preparation of an antiviral agent |
US5185463A (en) * | 1991-10-02 | 1993-02-09 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5237096A (en) * | 1991-10-02 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5218142A (en) * | 1991-10-02 | 1993-06-08 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5525726A (en) * | 1991-10-02 | 1996-06-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
US5237095A (en) * | 1991-10-02 | 1993-08-17 | E. R. Squibb & Sons, Inc. | Process for the preparation of an antiviral agent |
DE4142568A1 (de) * | 1991-12-21 | 1993-06-24 | Basf Ag | Verfahren zur herstellung von 2,4,5-triamino-6-halogenopyrimidinen und 2-amino-6-halogenopurinen |
EP0554025A3 (en) * | 1992-01-27 | 1993-11-18 | Squibb & Sons Inc | Fluorinated cyclobutyl purines and pyrimidines |
US5412134A (en) * | 1992-05-26 | 1995-05-02 | E. R. Squibb & Sons, Inc. | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol |
GB9220585D0 (en) * | 1992-09-30 | 1992-11-11 | Smithkline Beecham Plc | Pharmaceuticals |
US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
CN1157563A (zh) * | 1994-09-06 | 1997-08-20 | 日本化药株式会社 | 软膏剂 |
IL117574A0 (en) * | 1995-04-03 | 1996-07-23 | Bristol Myers Squibb Co | Processes for the preparation of cyclobutanone derivatives |
WO1998052930A1 (fr) * | 1997-05-20 | 1998-11-26 | Nippon Kayaku Kabushiki Kaisha | Nouveaux derives de cyclobutane et leur procede de production |
US6060458A (en) * | 1998-02-13 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use |
KR101358626B1 (ko) * | 2008-11-27 | 2014-02-04 | 고쿠리츠다이가쿠호우징 카가와다이가쿠 | 시클로부틸 푸린 유도체, 혈관신생 촉진제, 관강 형성 촉진제, 신경세포 성장 촉진제 및 의약품 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4177348A (en) * | 1977-12-13 | 1979-12-04 | United States Government | Carbocyclic analogs of cytosine nucleosides |
US4232154A (en) * | 1977-12-13 | 1980-11-04 | United States Of America | Carbocyclic analogs of cytosine nucleosides exhibiting antiviral and antineoplasticactivity |
US4617304A (en) * | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
EP0184473A1 (en) * | 1984-10-26 | 1986-06-11 | Merck & Co. Inc. | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives |
US4801710A (en) * | 1984-10-26 | 1989-01-31 | Merck & Co., Inc. | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives |
US4743689A (en) * | 1984-11-20 | 1988-05-10 | Nippon Kayaku Kabushiki Kaisha | Antibiotic derivative of adenine |
IN164556B (ko) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
JPS62208295A (ja) * | 1986-03-07 | 1987-09-12 | Nippon Kayaku Co Ltd | ヒポキサンチン塩基を有する新規化合物およびその製造法 |
US4782062A (en) * | 1987-05-11 | 1988-11-01 | Merck & Co., Inc. | 9-(2-hydroxymethyl)cycloalkylmethyl) guanines |
US4855466A (en) * | 1987-12-28 | 1989-08-08 | E. R. Squibb & Sons, Inc. | Purinyl cyclobutanes |
AU622926B2 (en) * | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
IL92096A0 (en) * | 1988-10-25 | 1990-07-12 | Abbott Lab | Carboxylic nucleoside analogs |
AU4378589A (en) * | 1988-10-25 | 1990-05-03 | Bristol-Myers Squibb Company | Carbocyclic nucleoside analogs |
US4918075A (en) * | 1988-12-20 | 1990-04-17 | E. R. Squibb & Sons, Inc. | Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
-
1989
- 1989-03-13 US US07/322,375 patent/US5723609A/en not_active Expired - Fee Related
- 1989-03-22 ZA ZA892185A patent/ZA892185B/xx unknown
- 1989-03-28 YU YU00637/89A patent/YU63789A/xx unknown
- 1989-03-28 CA CA000594809A patent/CA1341201C/en not_active Expired - Fee Related
- 1989-03-29 AR AR89313534A patent/AR247395A1/es active
- 1989-03-29 AT AT89105500T patent/ATE158797T1/de not_active IP Right Cessation
- 1989-03-29 IL IL89796A patent/IL89796A/xx not_active IP Right Cessation
- 1989-03-29 DE DE68928353T patent/DE68928353T2/de not_active Expired - Fee Related
- 1989-03-29 NO NO891322A patent/NO168423C/no not_active IP Right Cessation
- 1989-03-29 IE IE96989A patent/IE81079B1/en not_active IP Right Cessation
- 1989-03-29 NZ NZ228490A patent/NZ228490A/en unknown
- 1989-03-29 SK SK1934-89A patent/SK278165B6/sk unknown
- 1989-03-29 ES ES89105500T patent/ES2109218T3/es not_active Expired - Lifetime
- 1989-03-29 RU SU894613846A patent/RU2041213C1/ru active
- 1989-03-29 PH PH38389A patent/PH26562A/en unknown
- 1989-03-29 DK DK151889A patent/DK170749B1/da not_active IP Right Cessation
- 1989-03-29 FI FI891492A patent/FI96420C/fi not_active IP Right Cessation
- 1989-03-29 KR KR1019890003979A patent/KR970009223B1/ko not_active IP Right Cessation
- 1989-03-29 CZ CS891934A patent/CZ278493B6/cs not_active IP Right Cessation
- 1989-03-29 HU HU891581A patent/HU203734B/hu not_active IP Right Cessation
- 1989-03-29 EP EP89105500A patent/EP0335355B1/en not_active Expired - Lifetime
- 1989-03-30 EG EG16389A patent/EG18734A/xx active
- 1989-03-30 AU AU32276/89A patent/AU616494B2/en not_active Ceased
- 1989-03-30 DD DD89327077A patent/DD280325A5/de unknown
- 1989-03-30 CN CN89101971A patent/CN1031054C/zh not_active Expired - Fee Related
- 1989-03-30 PL PL1989278545A patent/PL158539B1/pl unknown
- 1989-03-30 PT PT90159A patent/PT90159B/pt active IP Right Grant
- 1989-03-30 JP JP1080214A patent/JP2694999B2/ja not_active Expired - Fee Related
- 1989-03-30 MX MX1546489A patent/MX15464A/es unknown
-
1991
- 1991-08-05 AU AU81625/91A patent/AU630570B2/en not_active Ceased
-
1992
- 1992-03-10 RU SU925011117A patent/RU2055076C1/ru not_active IP Right Cessation
-
1997
- 1997-05-07 BR BR1100660-9A patent/BR1100660A/pt active IP Right Grant
- 1997-12-17 GR GR970403344T patent/GR3025693T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890014544A (ko) | 비스(히드록시메틸)시클로부틸 푸린 및 피리미딘 | |
KR920008043A (ko) | 히드록시메틸(메틸렌시클로펜틸)푸린 및 피리미딘 | |
KR890009929A (ko) | 푸리닐 시클로부탄 및 피리미디닐 시클로부탄 | |
GB812366A (en) | Improvements in and relating to derivatives of pyrimidine and the preparation thereof | |
KR840002827A (ko) | 2-[4-[(4,4-디알킬-2,6-피페리딘디온-1-일)부틸]피페라지닐] 피리미딘류의 제조 | |
DK145344C (da) | Analogifremgangsmaade til fremstilling af 8-phenyl-puriner eller syreadditionssalte heraf | |
KR850006404A (ko) | 니트로 메틸렌 유도체의 제조방법 | |
IE33933L (en) | Quinazolinones | |
KR880013937A (ko) | 옥세타노신 유도체 | |
ATE12232T1 (de) | Trisubstituierte pyrimido(5,4-d)pyrimidine, ihre herstellung und diese enthaltende arzneimittel. | |
ATE160340T1 (de) | Konformationell festgelegte nukleosidanaloge | |
KR860001808A (ko) | 이미다조〔1,5-a〕피리미딘 유도체의 제조방법 | |
KR890014542A (ko) | 4-치환된 피라졸로[3,4-d] 피리미딘 유도체 | |
ES541780A0 (es) | Tetrahidrotienopiridinas | |
KR970705341A (ko) | 유충을 제어하는 방법과 조성물(compositions and methods for controlling pest insects) | |
PT74293B (pt) | Chemical methods and intermediates for preparing substituted pyrimidinones | |
KR890002103A (ko) | 피페리딘 유도체, 그의제법 및 도르지발 38 | |
GB1488337A (en) | Pharmaceutically useful hetero-fused pyrimidine derivatives | |
KR890002111A (ko) | 벤즈이미다졸 유도체, 그의 제법 및 치료에의 이용 | |
ATE15653T1 (de) | Mikrobizide acylanilin- und acylnaphthylaminderivate, verfahren zu deren herstellung und ihre verwendung. | |
JPS5587777A (en) | Pyrimidine derivative, its preparation and antitumorigenic agent | |
KR920002601A (ko) | 신규 핵산 유도체 | |
DK262879A (da) | Imidazo (1,2-a) imidazolforbindelser eller syreadditionssalte deraf fremgangsmaade til deres fremstilling samt deres anvendelse | |
DK1490368T3 (da) | 2,2-bis(hydroxymethyl)cyclopropylidenmethyl-puriner og pyrimidiner som antivirale midler | |
DE2720771B2 (de) | 2,4-Diamino-5-(3,5-dimethoxy-4thloalkylbenyD-pyrimidine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20031106 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee |